Skip to Main Navigation
Skip to Page Content
COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/35972

Pulegone: Target Organs and Levels of Evidence for TR-563

Toxicology and Carcinogenesis Studies of Pulegone (CAS No. 89-82-7) in F344/N Rats and B6C3F1 Mice (Gavage Studies)

Chemical (Study Title)
CASRN		Peer Review DateRoute/Exposure LevelsStudy Laboratory
Pulegone
89-82-7		11/19/2009Gavage
MALE RATS: 0, 18.75, 37.5, OR 75 MG/KG; FEMALE RATS AND MALE & FEMALE MICE: 0, 37.5, 75, OR 150 MG/KG		Battelle Columbus Laboratory

Levels of Evidence

Male Rats: No Evidence
TypeOrgan/Tissue (Lesion)
Non-Neoplastic Lesions
  • Kidney: Hyaline glomerulopathy; severity of nephropathy; cyst
  • Liver: Hepatocyte, cellular alteration, diffuse; fatty change; bile duct cyst; hepatocyte, necrosis; oval cell, hyperplasia; bile duct, hyperplasia; portal fibrosis
  • Nasal Cavity: Olfactory epithelium, degeneration
  • Forestomach: Inflammation; perforation; ulcer; epithelium, hyperplasia
Female Rats: Some Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Urinary Bladder: Papilloma 0/50 0/49 1/50 3/47 papilloma or carcinoma 0/50 0/49 1/50 5/47
Non-Neoplastic Lesions
  • Kidney: Hyaline glomerulopathy; nephropathy; severity of nephropathy
  • Liver: Hepatocyte, cellular alteration, diffuse; fatty change; bile duct, cyst; hepatocyte, necrosis; oval cell, hyperplasia; bile duct, hyperplasia; portal fibrosis
  • Nasal Cavity: Olfactory epithelium, degeneration, metaplasia; respiratory inflammation
Male Mice: Clear Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Liver: Hepatocellular: Adenoma 22/50 31/50 35/50 28/50 adenoma, carcinoma, or hepatoblastoma 29/50 37/50 42/50 36/50
Non-Neoplastic Lesions
  • Kidney: Glomerulopathy, hyaline; glomerulus, congestion; severity of nephropathy
  • Liver: Clear cell focus; eosinophilic focus; mixed cell focus; fatty change, focal; centrilobular, hepatocyte, hypertrophy; vein, intravascular hepatocyte; necrosis; bile duct, cyst; bile duct, hyperplasia; oval cell hyperplasia
  • Nasal Cavity: Olfactory epithelium, degeneration; inflammation; nerve, atrophy; epithelium, metaplasia
  • Forestomach: Hyperplasia, squamous; inflammation; ulcer
Female Mice: Clear Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Liver: Hepatocellular: Adenoma 13/49 15/50 13/50 27/50 adenoma, carcinoma or hepatoblastoma 17/49 15/50 15/50 33/50
May Have Been Related
  • All Organs: Osteoma or osteosarcoma: 0/49 0/50 3/50 1/50
Non-Neoplastic Lesions
  • Kidney: Glomerulopathy, hyaline; mineralization; nephropathy; glomerulus, congestion
  • Liver: Clear cell focus; eosinophilic focus; mixed cell focus; fatty change, focal; centrilobular, hepatocyte, hypertrophy; vein, intravascular hepatocyte; necrosis; pigmentation; bile duct, cyst; bile duct, hyperplasia; oval cell hyperplasia
  • Nasal Cavity: Olfactory epithelium, degeneration; inflammation; nerve, atrophy; epithelium, metaplasia
  • Forestomach: Hyperplasia, squamous; inflammation